Financial Summary

Mirati Therapeutics Inc  (MRTX)  $223.41    (%)

  • Symbol
    MRTX
    Price
    223.41$
    Beta
    1.99073
    Volume Avrg.
    530466
    Market Cap
    11233300500
    Last Div
    0
    Range
    66.01-240.58
    Changes
    -1.59
    Changes Percentage
    Exchange
    NASDAQ Capital Market
    Industry
    Biotechnology
    Ceo
    Dr. Charles Baum
    Sector
    Healthcare

About company

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and sitravatinib, a spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.


Income Statement

YearRevenueCost of revenuesGross profitOperating expensessOperating incomesInterest expenseIncome tax expensesEarnings before taxsNet incomeEarnings per share basicsEarnings per share dilutedsDividend per sharesGross marginsEBIT marginsProfit marginsEBITDAEBITEarnings Before Tax MarginsNet Profit Margins
2020220747.00 151286.00 104956.00 38668.0066288.002873.00968.0067091.0057411.003.308587268217793.280.8033334143460.4754583301250.3002894716580.26007601462377344.0066288.000.3039271201870.260076014623
2019260174.00 161782.00 98392.00 34462.006393.003576.0010481.0065737.0055256.0011.9711.893.037054038220.378177681090.2457201718850.2123809450676477.006393.000.2526655238420.21238094506
2018265595.00 163756.00 101839.00 30941.0070898.00324.0013372.0072903.0059531.0012.0111.912.742340216980.38343718820.2669402661950.22414202074681801.0070898.000.2744893540920.224142020746
2017229234.00 141048.00 88186.00 26842.0061344.002323.0015738.0064089.0048351.009.279.212.431406868490.3846986049190.2676042820870.21092420845171501.0061344.000.2795789455320.210924208451
2016215639.00 131376.00 84263.00 24239.0060024.001456.0015685.0061372.0045687.008.358.312.208978050390.3907595564810.2783541010670.21186798306470529.0060024.000.2846052893960.211867983064
2015233715.00 140089.00 93626.00 22396.007123.00733.0019121.0072515.0053394.009.289.221.995660676580.4005990201740.3047729071730.22845773698782487.007123.000.3102710566290.228457736987
2014182795.00 112258.00 70537.00 18034.0052503.00384.0013973.0053483.003951.006.496.451.8171831440.3858803577780.2872233923250.21614376760960449.0052503.000.2925845892940.216143767609
201317091.00 106606.00 64304.00 15305.0048999.00136.0013118.0050155.0037037.0040.0339.7511.3388761160.3762448072080.2866947516240.21670469837955756.0048999.000.2934585454330.216704698379
2012156508.00 87846.00 68662.00 13421.0055241.000.001403.0055763.0041733.0044.6444.152.631815561350.4387123980880.352959593120.26665090602458518.0055241.000.3562948858840.266650906024
2011108249.00 64431.00 43818.00 10028.003379.000.008283.0034205.0025922.0028.0527.680.00.4047889587890.3121506896140.23946641539435604.003379.000.3159844432740.239466415394
201065225.00 39541.00 25684.00 7299.0018385.000.004527.001854.0014013.0015.4115.150.00.3937753928710.2818704484480.21484093522419412.0018385.000.2842468378690.214840935224
200942905.00 25683.00 17222.00 5482.001174.000.003831.0012066.008235.001.3171.2970.00.40140.28120.192128.0012066.000.28120.1919
Year202020192018201720162015201420132012201120102009
Revenue220747.00260174.00265595.00229234.00215639.00233715.00182795.0017091.00156508.00108249.0065225.0042905.00
Cost of revenues151286.00161782.00163756.00141048.00131376.00140089.00112258.00106606.0087846.0064431.0039541.0025683.00
Gross profit 104956.00 98392.00 101839.00 88186.00 84263.00 93626.00 70537.00 64304.00 68662.00 43818.00 25684.00 17222.00
Operating expensess38668.0034462.0030941.0026842.0024239.0022396.0018034.0015305.0013421.0010028.007299.005482.00
Operating incomes66288.006393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.001174.00
Interest expense2873.003576.00324.002323.001456.00733.00384.00136.000.000.000.000.00
Income tax expenses968.0010481.0013372.0015738.0015685.0019121.0013973.0013118.001403.008283.004527.003831.00
Earnings before taxs67091.0065737.0072903.0064089.0061372.0072515.0053483.0050155.0055763.0034205.001854.0012066.00
Net income57411.0055256.0059531.0048351.0045687.0053394.003951.0037037.0041733.0025922.0014013.008235.00
Earnings per share basics3.3085872682177911.9712.019.278.359.286.4940.0344.6428.0515.411.317
Earnings per share diluteds3.2811.8911.919.218.319.226.4539.7544.1527.6815.151.297
Dividend per shares0.83.042.742.432.2121.8211.342.63000
Gross margins0.480.380.380.380.390.40.390.380.440.40.390.4
EBIT margins0.30.250.270.270.280.30.290.290.350.310.280.28
Profit margins0.260.210.220.210.210.230.220.220.270.240.210.19
EBITDA77344.0076477.0081801.0071501.0070529.0082487.0060449.0055756.0058518.0035604.0019412.00128.00
EBIT66288.006393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.0012066.00
Earnings Before Tax Margins0.30.250.270.280.280.310.290.290.360.320.280.28
Net Profit Margins0.260.210.220.210.210.230.220.220.270.240.210.19